Clinical diagnosis of malignant pleural mesothelioma

被引:39
作者
Bianco, Andrea [1 ]
Valente, Tullio [2 ]
De Rimini, Maria Luisa [3 ]
Sica, Giacomo [2 ]
Fiorelli, Alfonso [4 ]
机构
[1] Univ Campania Luigi Vanvitelli, Dept Cardiothorac & Resp Sci, Naples, Italy
[2] Hosp Monaldi, AORN Colli, Dept Radiol, Naples, Italy
[3] Hosp Monaldi, AORN Colli, Unit Nucl Med, Naples, Italy
[4] Univ Campania Luigi Vanvitelli, Thorac Surg Unit, Dept Cardiothorac & Resp Sci, Naples, Italy
关键词
Pleural mesothelioma; malignant pleural mesothelioma (MPM); clinical diagnosis; EPITHELIAL-CELLS; NITRIC-OXIDE; EXPRESSION; ASBESTOS; TUMOR; CLASSIFICATION; GUIDELINES; MANAGEMENT; PREDICTOR; BARD1;
D O I
10.21037/jtd.2017.10.09
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Malignant pleural mesothelioma (MPM) is a tumour which, despite progress in diagnostic procedures and biomolecular research, has poor prognosis. Symptoms reflect extension of disease and include shortness of breath and chest pain. Unexplained pleural effusion and pleural pain in patients exposed to asbestos should raise the suspicion of MPM. MPM diagnosis requires imaging procedures X-ray and computed tomography (CT) scans; magnetic resonance imaging (MRI) better defines the extension of the tumor while PET scanning provides additional information on metabolic activity, metastases, and response to treatment. Thoracoscopic biopsy remains the most appropriate procedure for definitive diagnosis of mesothelioma. Multimodality treatment including surgery, chemotherapy and radiotherapy has been associated with a better survival in selected patients. Clinical translational research including new approaches targeting immune-checkpoints is opening new horizons which may lead to personalised treatments.
引用
收藏
页码:S253 / S261
页数:9
相关论文
共 43 条
[31]   BARD1 serum autoantibodies for the detection of lung cancer [J].
Pilyugin, Maxim ;
Descloux, Pascaline ;
Andre, Pierre-Alain ;
Laszlo, Viktoria ;
Dome, Balazs ;
Hegedus, Balazs ;
Sardy, Sylvain ;
Janes, Samuel ;
Bianco, Andrea ;
Laurent, Geoffrey J. ;
Irminger-Finger, Irmgard .
PLOS ONE, 2017, 12 (08)
[32]   BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study [J].
Righi, Luisella ;
Duregon, Eleonora ;
Vatrano, Simona ;
Izzo, Stefania ;
Giorcelli, Jessica ;
Rondon-Lagos, Milena ;
Ascoli, Valeria ;
Ruffini, Enrico ;
Ventura, Laura ;
Volante, Marco ;
Papotti, Mauro ;
Scagliotti, Giorgio Vittorio .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) :2006-2017
[33]   Medical progress - Advances in malignant mesothelioma [J].
Robinson, BWS ;
Lake, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (15) :1591-1603
[34]   Malignant mesothelioma [J].
Rudd, R. M. .
BRITISH MEDICAL BULLETIN, 2010, 93 (01) :105-123
[35]   Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database [J].
Rusch, Valerie W. ;
Giroux, Dorothy .
ANNALS OF CARDIOTHORACIC SURGERY, 2012, 1 (04) :438-448
[36]  
Scherpereel A, 2010, EUR RESPIR J, V35, P479, DOI [10.1183/09031936.00063109, 10.3779/j.issn.1009-3419.2010.10.14]
[37]  
Sebastien P, 1980, IARC Sci Publ, P237
[38]  
Vilchez RA, 2004, CLIN MICROBIOL REV, V17, P495, DOI [10.1128/CMR.17.3.495-508.2004, 10.1128/cmr.17.3.495-508.2004]
[39]   Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient [J].
Wald, Ori ;
Sugarbaker, David J. .
JOURNAL OF THORACIC DISEASE, 2017, 9 (03) :485-489
[40]   Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis [J].
Wu, JY ;
Vlastos, AT ;
Pelte, MF ;
Caligo, MA ;
Bianco, A ;
Krause, KH ;
Laurent, GJ ;
Irminger-Finger, I .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (05) :1215-1226